



## Press Release

Montrouge, France, February 10, 2020

### **DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference**

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Ramzi Benamar, Chief Financial Officer, will present at the SVB Leerink 9th Annual Global Healthcare Conference in New York, NY, on Wednesday, February 26, 2020, at 1:00pm EST.

A live webcast of the presentation will be available on the Investors & Media section of the Company's website: <https://www.dbv-technologies.com/investor-relations/>. A replay of the presentation will also be available on DBV's website after the event.

#### **About DBV Technologies**

DBV Technologies is developing Viaskin<sup>®</sup>, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<sup>™</sup>, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

#### **DBV Investor Relations Contact**

Sara Blum Sherman  
Senior Director, Investor Relations & Strategy  
+1 212-271-0740  
[sara.sherman@dbv-technologies.com](mailto:sara.sherman@dbv-technologies.com)



DBV Media Contact

Joe Becker

VP, Global Corporate Communications

+1 646-650-3912

[joseph.becker@dbv-technologies.com](mailto:joseph.becker@dbv-technologies.com)